Journal Mobile Options
Table of Contents
Vol. 74, No. 5, 2005
Issue release date: August 2005

Effects of Mind-Body Therapy on Quality of Life and Neuroendocrine and Cellular Immune Functions in Patients with Ulcerative Colitis

Elsenbruch S. · Langhorst J. · Popkirowa K. · Müller T. · Luedtke R. · Franken U. · Paul A. · Spahn G. · Michalsen A. · Janssen O.E. · Schedlowski M. · Dobos G.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: The aim of this study was to investigate the effects of mind-body therapy on neuroendocrine and cellular immune measures, health-related quality of life and disease activity in patients with ulcerative colitis (UC) in remission. Methods: Thirty UC patients in remission or with low disease activity were randomly assigned to an intervention group (n = 15) or a usual-care waiting control group (n = 15). Intervention consisted of a structured 60-hour training program over 10 weeks which included stress management training, moderate exercise, Mediterranean diet, behavioral techniques and self-care strategies. Quality of life, perceived stress and disease activity were assessed with standardized questionnaires (IBDQ, SF-36, PSS, CAI). In addition, the distribution of circulating lymphocytes and lymphocyte subsets as well as the β-adrenergic modulation of TNF-α production in vitro were analyzed. Urine catecholamines and plasma cortisol, prolactin and growth hormone were measured pre- and postinterventionally, and were compared with a healthy control group (n = 10). Results: In response to therapy, patients in the intervention group showed significantly greater improvement in the SF-36 scale Mental Health and the Psychological Health Sum score compared with changes observed in the usual-care waiting control group. Patients in the intervention group showed significantly greater improvement on the IBDQ scale Bowel Symptoms compared with the control group. However, no significant group differences in circulating lymphocyte subsets or endocrine parameters were observed in response to therapy. In addition, no significant effects of intervention on either the basal levels of TNF-α or the suppressive action of the β-adrenergic agonist isoproterenol on TNF-α production were observed. Conclusion: Mind-body therapy may improve quality of life in patients with UC in remission, while no effects of therapy on clinical or physiological parameters were found, which may at least in part be related to selective patient recruitment.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Fiocchi C: Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998;1158:182–205.
  2. Langholz E, Munkholm P, Davidsen M, Binder V: Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992;103:1444–1451.
  3. Ekbom A, Helmick CG, Zack M, Holmberg L, Adami HO: Survival and causes of death in patients with inflammatory bowel disease: A population-based study. Gastroenterology 1992;103:954–960.
  4. Levenstein S, Li Z, Almer S, Barbosa A, Marquis P, Moser G, Sperber A, Toner B, Drossman DA: Cross-cultural variation in disease-related concerns among patients with inflammatory bowel disease. Am J Gastroenterol 2001;96:1822–1830.
  5. Casellas F, Lopez-Vivancos J, Casado A, Malagelada JR: Factors affecting health related quality of life of patients with inflammatory bowel disease. Qual Life Res 2002;11:775–781.
  6. Russel MG, Nieman FH, Bergers JM, Stockbrugger RW: Cigarette smoking and quality of life in patients with inflammatory bowel disease. South Limburg IBD Study Group. Eur J Gastroenterol Hepatol 1996;8:1075–1081.
  7. Janke KH, Raible A, Bauer M, Clemens P, Meisner C, Hauser W, Steder-Neukamm U, Henrich G, Herschbach P, Gregor M, Klump B: Questions on life satisfaction (FLZ(M)) in inflammatory bowel disease. Int J Colorectal Dis 2003.
  8. Petrak F, Hardt J, Clement T, Borner N, Egle UT, Hoffmann SO: Impaired health-related quality of life in inflammatory bowel diseases: Psychosocial impact and coping styles in a national German sample. Scand J Gastroenterol 2001;36:375–382.
  9. Smith GD, Watson R, Roger D, McRorie E, Hurst N, Luman W, Palmer KR: Impact of a nurse-led counselling service on quality of life in patients with inflammatory bowel disease. J Adv Nurs 2002;38:152–160.
  10. Arapakis G, Lyketsos CG, Gerolymatos K, Richardson SC, Lyketsos GC: Low dominance and high intropunitiveness in ulcerative colitis and irritable bowel syndrome. Psychother Psychosom 1986;46:171–176.
  11. Porcelli P, Taylor GJ, Bagby RM, De Carne M: Alexithymia and functional gastrointestinal disorders. A comparison with inflammatory bowel disease. Psychother Psychosom 1999;68:263–269.
  12. Verissimo R, Mota-Cardoso R, Taylor G: Relationships between alexithymia, emotional control, and quality of life in patients with inflammatory bowel disease. Psychother Psychosom 1998;67:75–80.
  13. Porcelli P, Zaka S, Leoci C, Centonze S, Taylor GJ: Alexithymia in inflammatory bowel disease. A case-control study. Psychother Psychosom 1995;64:49–53.
  14. Feldman F, Cantor D, Soll S, Bachrach W: Psychiatric study of a consecutive series of 34 patients with ulcerative colitis. BMJ 1967;3:14–17.
  15. Hislop IG: Onset setting in inflammatory bowel disease. Med J Aust 1974;1:981–984.
  16. Fava GA, Pavan L: Large bowel disorders. I. Illness configuration and life events. Psychother Psychosom 1976–77;27:93–99.
  17. Greene BR, Blanchard EB, Wan CK: Long-term monitoring of psychosocial stress and symptomatology in inflammatory bowel disease. Behav Res Ther 1994;32:217–226.
  18. Maunder R, Esplen MJ: Facilitating adjustment to inflammatory bowel disease: A model of psychosocial intervention in non-psychiatric patients. Psychother Psychosom 1999;68:230–240.
  19. Casellas F, Lopez-Vivancos J, Badia X, Vilaseca J, Malagelada JR: Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol 2001;13:567–572.
  20. Gaab J, Blättler N, Menzi T, Pabst B, Stoyer S, Ehlert U: Randomized controlled evaluation of the effects of cognitive-behavioral stress management on cortisol responses to acute stress in healthy subjects. Psychoneuroendocrinology 2003;28:767–779.
  21. Cohen S, Kamarck T, Mermelstein R: A global measure of perceived stress. J Health Soc Behav 1983;24:385–396.
  22. Hauser W, Dietz N, Grandt D, Steder-Neukamm U, Janke KH, Stein U, Stallmach A: Validation of the inflammatory bowel disease questionnaire IBDQ-D, German version, for patients with ileal pouch anal anastomosis for ulcerative colitis. Z Gastroenterol 2004;42:131–139.
  23. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004;126:402–413.
  24. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C: A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804–810.
  25. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, Kinnear D, Saibil F, McDonald JW: Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287–296.
  26. Love JR, Irvine EJ, Fedorak RN: Quality of life in inflammatory bowel disease. J Clin Gastroenterol 1992;14:15–19.
  27. Mitchell A, Guyatt G, Singer J, Irvine EJ, Goodacre R, Tompkins C, Williams N, Wagner F: Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol 1988;10:306–310.
  28. McHorney CA, Ware JE, Lu R, Sherbourne CD: The MOS 36-item Short Form Health Survey (SF-36). III. Test of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40–66.
  29. McHorney CA, Ware JE Jr, Raczek AE: The MOS 36-Item Short-Form Health Survey (SF-36). II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247–263.
  30. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–483.
  31. Bullinger M, Kirchberger I, Ware J: The German SF-36 Health Survey. Translation and psychometric testing of a generic instrument for the assessment of health-related quality of life. Z Gesundheitswiss 1995;3:21–36.
  32. Rachmilewitz D: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomized trial. BMJ 1989;298:82–86.
  33. Truelove SC, Witts LJ: Cortisone in ulcerative colitis: Final report on a therapeutic trial. BMJ 1955;1041–1048.
  34. Miller GE, Cohen S: Psychological interventions and the immune system: A meta-analytic review and critique. Health Psychol 2001;20:47–63.
  35. Kemeny ME , Miller E: Effects of psychosocial interventions on the immune system; in Schedlowski M, Tewes U (eds): Psychoneuroimmunology. An Interdisciplinary Introduction. New York, Kluwer Academic/Plenum Publishers, 1999.
  36. Castillo-Richmond A, Schneider RH, Alexander CN, Cook R, Myers H, Nidich S, Haney C, Rainforth M, Salerno J: Effects of stress reduction on carotid atherosclerosis in hypertensive African Americans. Stroke 2000;31:568–573.
  37. Domar AD, Seibel MM, Benson H: The mind/body program for infertility: A new behavioral treatment approach for women with infertility. Fertil Steril 1990;53:246–249.
  38. Hellman CJ, Budd M, Borysenko J, McClelland DC, Benson H: A study of the effectiveness of two group behavioral medicine interventions for patients with psychosomatic complaints. Behav Med 1990;16:165–173.
  39. Caudill M, Schnable R, Zuttermeister P, Benson H, Friedman R: Decreased clinic use by chronic pain patients: Response to behavioral medicine intervention. Clin J Pain 1991;7:305–310.
  40. Schneider RH, Staggers F, Alxander CN, Sheppard W, Rainforth M, Kondwani K, Smith S, King CG: A randomised controlled trial of stress reduction for hypertension in older African Americans. Hypertension 1995;26:820–827.
  41. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ: Intensive lifestyle changes for reversal of coronary heart disease. JAMA 1998;280:2001–2007.
  42. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL: Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990;336:129–133.
  43. Kabat-Zinn J: Full Catastrophe Living: Using the Wisdom of Your Body and Mind to Face Stress, Pain and Illness. Delacorte, New York, 1990.
  44. Benson H, Stuart EM: The Wellness Book: The Comprehensive Guide to Maintaining Health and Treating Stress-Related Illness. New York, Simon & Schuster, 1992.
  45. Schwarz SP, Blanchard EB: Evaluation of a psychological treatment for inflammatory bowel disease. Behav Res Ther 1991;29:167–177.
  46. Jantschek G, Zeitz M, Pritsch M, Wirsching M, Klor HU, Studt HH, Rasenack J, Deter HC, Riecken EO, Feiereis H, Keller W: Effects of psychotherapy on the course of Crohn’s disease. German study group on psychosocial intervention in Crohn’s Disease. Scand J Gastroenterol 1998;33:1289–1296.
  47. Maunder R, Esplen MJ: Supportive-expressive group psychotherapy for persons with inflammatory bowel disease. Can J Psychiatry 2001;46:622–626.
  48. Larsson K, Sundberg Hjelm M, Karlbom U, Nordin K, Anderberg UM, Loof L: A group-based patient education programme for high-anxiety patients with Crohn disease or ulcerative colitis. Scand J Gastroenterol 2003;38:763–769.
  49. Shaw L, Ehrlich A: Relaxation training as a treatment for chronic pain caused by ulcerative colitis. Pain 1987 29;287–293.
  50. Milne B, Joachim G, Niedhardt J: A stress management programme for inflammatory bowel disease. J Adv Nurs 1986;11:561–567.
  51. Mittermaier C, Dejaco C, Waldhoer T, Oefferlbauer-Ernst A, Miehsler W, Beier M, Tillinger W, Gangl A, Moser G: Impact of depressive mood on relapse in patients with inflammatory bowel disease: A prospective 18-months follow-up study. Psychosom Med 2004;66;79–84.
  52. Levenstein S, Prantera C, Varvo V, Scribano ML, Berto E, Andreoli A, Luzi C: Psychological stress and disease activity in ulcerative colitis: A multidimensional cross-sectional study. Am J Gastroenterol 1994;89:1219–1225.
  53. Levenstein S, Prantera C, Varvo V, Scribano ML, Andreoli A, Luzi C, Arca M, Berto E, Milite G, Marcheggiano A: Stress and exacerbation in ulcerative colitis: A prospective study of patients enrolled in remission. Am J Gastroenterol 2000;95:1213–1220.
  54. von Wietersheim J, Kohler T, Feiereis H: Relapse-precipitating life events and feelings in patients with inflammatory bowel disease. Psychother Psychosom 1992;58:103–112.
  55. North CS, Alpers DH, Helzer JE, Spitznagel EL, Cluse RE: Do life events or depression exacerbate inflammatory bowel disease? A prospective study. Ann Int Med 1991;114:381–386.
  56. Duffy LC, Zielezny MA, Marshall JR, Weiser MM, Phillips JF, Byers TE, Calkins BM, Graham S, Ogra PL: Lag time between stress events and risk of recurrent episodes of inflammatory bowel disease. Epidemiology 1991;2:141–145.
  57. Duffy LC, Zielezny MA, Marshall JR, Byers TE, Weiser MM, Phillips JF, Calkins BM, Ogra PL, Graham S: Relevance of major stress events as an indicator of disease activity prevalence in inflammatory bowel disease. Behav Med 1991;17:101–110.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50